Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids
BackgroundA recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs).Ob...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2021.768474/full |
| _version_ | 1819279044653350912 |
|---|---|
| author | Justine Keathley Justine Keathley Véronique Garneau Véronique Garneau Valérie Marcil Valérie Marcil David M. Mutch Julie Robitaille Julie Robitaille Iwona Rudkowska Iwona Rudkowska Gabriela Sofian Sophie Desroches Sophie Desroches Marie-Claude Vohl Marie-Claude Vohl |
| author_facet | Justine Keathley Justine Keathley Véronique Garneau Véronique Garneau Valérie Marcil Valérie Marcil David M. Mutch Julie Robitaille Julie Robitaille Iwona Rudkowska Iwona Rudkowska Gabriela Sofian Sophie Desroches Sophie Desroches Marie-Claude Vohl Marie-Claude Vohl |
| author_sort | Justine Keathley |
| collection | DOAJ |
| description | BackgroundA recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs).ObjectiveTo provide guidance for clinical practice related to genetic testing for evaluating responsiveness to dietary/supplemental omega-3s and their impact on plasma lipids/lipoproteins/apolipoproteins.DesignUsing the results of the abovementioned systematic review, the first CPGs in nutrigenetics were developed using the established GRADE methodology and AGREE II approach.ResultsThree clinical practice recommendations were developed. Most gene-diet associations identified in the literature lack adequate scientific and clinical validity to warrant consideration for implementing in a practice setting. However, two gene-diet associations with strong evidence (GRADE quality: moderate and high) can be considered for implementation into clinical practice in certain cases: male APOE-E4 carriers (rs429358, rs7412) and TG changes in response to the omega-3 fatty acids eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) as well as a 31-SNP nutrigenetic risk score and TG changes in response to EPA+DHA among adults with overweight/obesity. Ethical and regulatory implications must be considered when providing APOE nutrigenetic tests given the well-established link between APOE genetic variation and Alzheimer's Disease.ConclusionMost of the evidence in this area is not ready for implementation into clinical practice primarily due to low scientific validity (low quality of evidence). However, the first CPGs in nutrigenetics have been developed for two nutrigenetic associations with strong scientific validity, related to dietary/supplemental omega-3 and TG responses. |
| first_indexed | 2024-12-24T00:21:39Z |
| format | Article |
| id | doaj.art-3641d5799f3f4771895b74152b466cae |
| institution | Directory Open Access Journal |
| issn | 2296-861X |
| language | English |
| last_indexed | 2024-12-24T00:21:39Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj.art-3641d5799f3f4771895b74152b466cae2022-12-21T17:24:33ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2022-02-01810.3389/fnut.2021.768474768474Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty AcidsJustine Keathley0Justine Keathley1Véronique Garneau2Véronique Garneau3Valérie Marcil4Valérie Marcil5David M. Mutch6Julie Robitaille7Julie Robitaille8Iwona Rudkowska9Iwona Rudkowska10Gabriela Sofian11Sophie Desroches12Sophie Desroches13Marie-Claude Vohl14Marie-Claude Vohl15Centre Nutrition, Santé et Société (NUTRISS), Institut sur la Nutrition et les Aliments Fonctionnels (INAF), Université Laval, Québec City, QC, CanadaSchool of Nutrition, Université Laval, Québec City, QC, CanadaCentre Nutrition, Santé et Société (NUTRISS), Institut sur la Nutrition et les Aliments Fonctionnels (INAF), Université Laval, Québec City, QC, CanadaSchool of Nutrition, Université Laval, Québec City, QC, CanadaResearch Centre, Sainte-Justine University Health Centre, Montréal, QC, CanadaDepartment of Nutrition, Université de Montréal, Montréal, QC, CanadaDepartment of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, CanadaCentre Nutrition, Santé et Société (NUTRISS), Institut sur la Nutrition et les Aliments Fonctionnels (INAF), Université Laval, Québec City, QC, CanadaSchool of Nutrition, Université Laval, Québec City, QC, CanadaEndocrinology and Nephrology Unit, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, QC, CanadaDepartment of Kinesiology, Université Laval, Québec City, QC, CanadaLibrary, Université Laval, Québec City, QC, CanadaCentre Nutrition, Santé et Société (NUTRISS), Institut sur la Nutrition et les Aliments Fonctionnels (INAF), Université Laval, Québec City, QC, CanadaSchool of Nutrition, Université Laval, Québec City, QC, CanadaCentre Nutrition, Santé et Société (NUTRISS), Institut sur la Nutrition et les Aliments Fonctionnels (INAF), Université Laval, Québec City, QC, CanadaSchool of Nutrition, Université Laval, Québec City, QC, CanadaBackgroundA recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs).ObjectiveTo provide guidance for clinical practice related to genetic testing for evaluating responsiveness to dietary/supplemental omega-3s and their impact on plasma lipids/lipoproteins/apolipoproteins.DesignUsing the results of the abovementioned systematic review, the first CPGs in nutrigenetics were developed using the established GRADE methodology and AGREE II approach.ResultsThree clinical practice recommendations were developed. Most gene-diet associations identified in the literature lack adequate scientific and clinical validity to warrant consideration for implementing in a practice setting. However, two gene-diet associations with strong evidence (GRADE quality: moderate and high) can be considered for implementation into clinical practice in certain cases: male APOE-E4 carriers (rs429358, rs7412) and TG changes in response to the omega-3 fatty acids eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) as well as a 31-SNP nutrigenetic risk score and TG changes in response to EPA+DHA among adults with overweight/obesity. Ethical and regulatory implications must be considered when providing APOE nutrigenetic tests given the well-established link between APOE genetic variation and Alzheimer's Disease.ConclusionMost of the evidence in this area is not ready for implementation into clinical practice primarily due to low scientific validity (low quality of evidence). However, the first CPGs in nutrigenetics have been developed for two nutrigenetic associations with strong scientific validity, related to dietary/supplemental omega-3 and TG responses.https://www.frontiersin.org/articles/10.3389/fnut.2021.768474/fullnutrigeneticsnutrigenomicslipidslipoproteinsapolipoproteinsomega-3 |
| spellingShingle | Justine Keathley Justine Keathley Véronique Garneau Véronique Garneau Valérie Marcil Valérie Marcil David M. Mutch Julie Robitaille Julie Robitaille Iwona Rudkowska Iwona Rudkowska Gabriela Sofian Sophie Desroches Sophie Desroches Marie-Claude Vohl Marie-Claude Vohl Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids Frontiers in Nutrition nutrigenetics nutrigenomics lipids lipoproteins apolipoproteins omega-3 |
| title | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
| title_full | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
| title_fullStr | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
| title_full_unstemmed | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
| title_short | Clinical Practice Guidelines Using GRADE and AGREE II for the Impact of Genetic Variants on Plasma Lipid/Lipoprotein/Apolipoprotein Responsiveness to Omega-3 Fatty Acids |
| title_sort | clinical practice guidelines using grade and agree ii for the impact of genetic variants on plasma lipid lipoprotein apolipoprotein responsiveness to omega 3 fatty acids |
| topic | nutrigenetics nutrigenomics lipids lipoproteins apolipoproteins omega-3 |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2021.768474/full |
| work_keys_str_mv | AT justinekeathley clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT justinekeathley clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT veroniquegarneau clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT veroniquegarneau clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT valeriemarcil clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT valeriemarcil clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT davidmmutch clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT julierobitaille clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT julierobitaille clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT iwonarudkowska clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT iwonarudkowska clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT gabrielasofian clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT sophiedesroches clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT sophiedesroches clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT marieclaudevohl clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids AT marieclaudevohl clinicalpracticeguidelinesusinggradeandagreeiifortheimpactofgeneticvariantsonplasmalipidlipoproteinapolipoproteinresponsivenesstoomega3fattyacids |